---
schema_version: "secwatch.filing_event.v1"
accession: "0001401914-26-000040"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2026-07-17T20:07:20+00:00"
generated_at: "2026-07-17T20:08:06.093376+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience receives Nasdaq delisting notice for equity deficiency; plans to request hearing

## Summary
- Nasdaq notified Daré on July 13, 2026 that stockholders' equity was below $2.5M as of March 31, 2026.
- Company also failed alternative compliance measures: $35M market value or $500K net income from continuing ops.
- Daré intends to timely request a hearing before a Nasdaq Hearing Panel to stay delisting.
- No assurance that the Panel will grant an extension or that the company will regain compliance.
- Non-compliance is with Nasdaq Listing Rule 5550(b); delisting risk remains.

## SEC filing metadata
- accession: 0001401914-26-000040
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2026-07-17T20:07:20+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000040/0001401914-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000040/dare-20260713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001401914-26-000040
- JSON: https://secwatch.observer/filing/0001401914-26-000040.json
- Plain text: https://secwatch.observer/filing/0001401914-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.